nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—UGT1A1—Etoposide—uterine cancer	0.0433	0.106	CbGbCtD
Nilotinib—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0428	0.105	CbGbCtD
Nilotinib—ABCG2—Dactinomycin—uterine cancer	0.0423	0.103	CbGbCtD
Nilotinib—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0299	0.073	CbGbCtD
Nilotinib—ABCG2—Carboplatin—uterine cancer	0.0284	0.0694	CbGbCtD
Nilotinib—CYP2C8—Progesterone—uterine cancer	0.0284	0.0693	CbGbCtD
Nilotinib—ABCG2—Etoposide—uterine cancer	0.0238	0.0583	CbGbCtD
Nilotinib—CYP2C9—Progesterone—uterine cancer	0.0198	0.0484	CbGbCtD
Nilotinib—ABCB1—Progesterone—uterine cancer	0.0192	0.0469	CbGbCtD
Nilotinib—CYP2D6—Progesterone—uterine cancer	0.0181	0.0442	CbGbCtD
Nilotinib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0174	0.0425	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—uterine cancer	0.0163	0.0397	CbGbCtD
Nilotinib—ABCB1—Dactinomycin—uterine cancer	0.0152	0.0372	CbGbCtD
Nilotinib—CYP2C8—Etoposide—uterine cancer	0.0127	0.031	CbGbCtD
Nilotinib—CYP3A4—Progesterone—uterine cancer	0.0115	0.0281	CbGbCtD
Nilotinib—CYP2B6—Doxorubicin—uterine cancer	0.0114	0.0279	CbGbCtD
Nilotinib—ABCB1—Etoposide—uterine cancer	0.0086	0.021	CbGbCtD
Nilotinib—ABCB1—Doxorubicin—uterine cancer	0.00586	0.0143	CbGbCtD
Nilotinib—CYP2D6—Doxorubicin—uterine cancer	0.00553	0.0135	CbGbCtD
Nilotinib—Ponatinib—FGFR2—uterine cancer	0.00544	1	CrCbGaD
Nilotinib—CYP3A4—Etoposide—uterine cancer	0.00515	0.0126	CbGbCtD
Nilotinib—CYP3A4—Doxorubicin—uterine cancer	0.00351	0.00858	CbGbCtD
Nilotinib—EPHA4—myometrium—uterine cancer	0.00105	0.00672	CbGeAlD
Nilotinib—TIE1—epithelium—uterine cancer	0.00104	0.00664	CbGeAlD
Nilotinib—CA3—myometrium—uterine cancer	0.00104	0.00664	CbGeAlD
Nilotinib—TIE1—uterine cervix—uterine cancer	0.00103	0.00658	CbGeAlD
Nilotinib—MAP4K1—decidua—uterine cancer	0.00103	0.00657	CbGeAlD
Nilotinib—TIE1—smooth muscle tissue—uterine cancer	0.001	0.0064	CbGeAlD
Nilotinib—MAPK11—female reproductive system—uterine cancer	0.000992	0.00634	CbGeAlD
Nilotinib—MAPK8—uterus—uterine cancer	0.000989	0.00633	CbGeAlD
Nilotinib—CDC42BPB—female reproductive system—uterine cancer	0.000983	0.00629	CbGeAlD
Nilotinib—TIE1—decidua—uterine cancer	0.000981	0.00627	CbGeAlD
Nilotinib—EPHB3—uterine cervix—uterine cancer	0.000979	0.00626	CbGeAlD
Nilotinib—FGR—myometrium—uterine cancer	0.000965	0.00617	CbGeAlD
Nilotinib—MAP4K1—mammalian vulva—uterine cancer	0.000944	0.00604	CbGeAlD
Nilotinib—EPHB4—myometrium—uterine cancer	0.000918	0.00587	CbGeAlD
Nilotinib—MAPK11—female gonad—uterine cancer	0.000902	0.00577	CbGeAlD
Nilotinib—EPHA2—myometrium—uterine cancer	0.000901	0.00576	CbGeAlD
Nilotinib—HCK—uterine cervix—uterine cancer	0.0009	0.00575	CbGeAlD
Nilotinib—CDC42BPB—female gonad—uterine cancer	0.000895	0.00572	CbGeAlD
Nilotinib—BRAF—endometrium—uterine cancer	0.000893	0.00571	CbGeAlD
Nilotinib—CDC42BPB—vagina—uterine cancer	0.000889	0.00569	CbGeAlD
Nilotinib—MAPK8—female reproductive system—uterine cancer	0.000889	0.00569	CbGeAlD
Nilotinib—EPHA6—female reproductive system—uterine cancer	0.000889	0.00569	CbGeAlD
Nilotinib—EPHB3—endometrium—uterine cancer	0.000885	0.00566	CbGeAlD
Nilotinib—TIE1—uterus—uterine cancer	0.000858	0.00549	CbGeAlD
Nilotinib—HCK—decidua—uterine cancer	0.000857	0.00548	CbGeAlD
Nilotinib—EPHB3—mammalian vulva—uterine cancer	0.000857	0.00548	CbGeAlD
Nilotinib—EPHB6—myometrium—uterine cancer	0.00084	0.00537	CbGeAlD
Nilotinib—CA7—renal system—uterine cancer	0.000824	0.00527	CbGeAlD
Nilotinib—BRAF—uterus—uterine cancer	0.000822	0.00526	CbGeAlD
Nilotinib—EPHB3—uterus—uterine cancer	0.000816	0.00522	CbGeAlD
Nilotinib—HCK—endometrium—uterine cancer	0.000814	0.0052	CbGeAlD
Nilotinib—MAPK8—female gonad—uterine cancer	0.000809	0.00518	CbGeAlD
Nilotinib—CA3—uterine cervix—uterine cancer	0.000808	0.00517	CbGeAlD
Nilotinib—MAPK8—vagina—uterine cancer	0.000804	0.00514	CbGeAlD
Nilotinib—HCK—mammalian vulva—uterine cancer	0.000787	0.00503	CbGeAlD
Nilotinib—TIE1—female reproductive system—uterine cancer	0.000771	0.00493	CbGeAlD
Nilotinib—MAPK14—epithelium—uterine cancer	0.00076	0.00486	CbGeAlD
Nilotinib—MAPK14—uterine cervix—uterine cancer	0.000754	0.00482	CbGeAlD
Nilotinib—LCK—uterine cervix—uterine cancer	0.000751	0.0048	CbGeAlD
Nilotinib—HCK—uterus—uterine cancer	0.00075	0.0048	CbGeAlD
Nilotinib—EPHB3—female reproductive system—uterine cancer	0.000734	0.00469	CbGeAlD
Nilotinib—MAPK14—smooth muscle tissue—uterine cancer	0.000733	0.00469	CbGeAlD
Nilotinib—MAP4K1—vagina—uterine cancer	0.000731	0.00468	CbGeAlD
Nilotinib—EPHB4—epithelium—uterine cancer	0.000721	0.00461	CbGeAlD
Nilotinib—MAP2K5—myometrium—uterine cancer	0.000718	0.00459	CbGeAlD
Nilotinib—MAPK14—decidua—uterine cancer	0.000718	0.00459	CbGeAlD
Nilotinib—FGR—decidua—uterine cancer	0.000715	0.00458	CbGeAlD
Nilotinib—LCK—decidua—uterine cancer	0.000715	0.00458	CbGeAlD
Nilotinib—EPHA4—mammalian vulva—uterine cancer	0.000715	0.00458	CbGeAlD
Nilotinib—EPHB4—uterine cervix—uterine cancer	0.000715	0.00457	CbGeAlD
Nilotinib—EPHA2—epithelium—uterine cancer	0.000707	0.00452	CbGeAlD
Nilotinib—MAPK14—renal system—uterine cancer	0.000705	0.00451	CbGeAlD
Nilotinib—TIE1—female gonad—uterine cancer	0.000702	0.00449	CbGeAlD
Nilotinib—EPHA2—uterine cervix—uterine cancer	0.000701	0.00448	CbGeAlD
Nilotinib—CSF1R—myometrium—uterine cancer	0.000701	0.00448	CbGeAlD
Nilotinib—EPHB4—smooth muscle tissue—uterine cancer	0.000695	0.00444	CbGeAlD
Nilotinib—TEK—epithelium—uterine cancer	0.00069	0.00441	CbGeAlD
Nilotinib—EPHA4—uterus—uterine cancer	0.000681	0.00436	CbGeAlD
Nilotinib—EPHB4—decidua—uterine cancer	0.000681	0.00436	CbGeAlD
Nilotinib—CA2—exocrine gland—uterine cancer	0.000681	0.00435	CbGeAlD
Nilotinib—FGR—endometrium—uterine cancer	0.000679	0.00434	CbGeAlD
Nilotinib—CA3—uterus—uterine cancer	0.000673	0.00431	CbGeAlD
Nilotinib—BRAF—female gonad—uterine cancer	0.000673	0.0043	CbGeAlD
Nilotinib—BRAF—vagina—uterine cancer	0.000669	0.00428	CbGeAlD
Nilotinib—EPHB4—renal system—uterine cancer	0.000669	0.00428	CbGeAlD
Nilotinib—EPHA2—decidua—uterine cancer	0.000668	0.00427	CbGeAlD
Nilotinib—EPHB3—female gonad—uterine cancer	0.000667	0.00427	CbGeAlD
Nilotinib—TEK—smooth muscle tissue—uterine cancer	0.000665	0.00425	CbGeAlD
Nilotinib—EPHB3—vagina—uterine cancer	0.000663	0.00424	CbGeAlD
Nilotinib—BLK—lymph node—uterine cancer	0.000658	0.00421	CbGeAlD
Nilotinib—LCK—mammalian vulva—uterine cancer	0.000657	0.0042	CbGeAlD
Nilotinib—FGR—mammalian vulva—uterine cancer	0.000657	0.0042	CbGeAlD
Nilotinib—EPHB6—uterine cervix—uterine cancer	0.000654	0.00418	CbGeAlD
Nilotinib—TEK—decidua—uterine cancer	0.000652	0.00417	CbGeAlD
Nilotinib—EPHB4—endometrium—uterine cancer	0.000646	0.00413	CbGeAlD
Nilotinib—TEK—renal system—uterine cancer	0.00064	0.00409	CbGeAlD
Nilotinib—KIT—myometrium—uterine cancer	0.000637	0.00407	CbGeAlD
Nilotinib—EPHA2—endometrium—uterine cancer	0.000634	0.00406	CbGeAlD
Nilotinib—MAPK14—uterus—uterine cancer	0.000628	0.00402	CbGeAlD
Nilotinib—LCK—uterus—uterine cancer	0.000626	0.004	CbGeAlD
Nilotinib—EPHB4—mammalian vulva—uterine cancer	0.000625	0.004	CbGeAlD
Nilotinib—EPHB6—decidua—uterine cancer	0.000623	0.00398	CbGeAlD
Nilotinib—PDGFRB—myometrium—uterine cancer	0.000622	0.00398	CbGeAlD
Nilotinib—TEK—endometrium—uterine cancer	0.000619	0.00396	CbGeAlD
Nilotinib—EPHA2—mammalian vulva—uterine cancer	0.000613	0.00392	CbGeAlD
Nilotinib—HCK—female gonad—uterine cancer	0.000613	0.00392	CbGeAlD
Nilotinib—EPHA4—female reproductive system—uterine cancer	0.000613	0.00392	CbGeAlD
Nilotinib—ABL1—Idarubicin—Epirubicin—uterine cancer	0.00061	0.173	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Epirubicin—uterine cancer	0.00061	0.173	CbGdCrCtD
Nilotinib—ABL1—Doxorubicin—Epirubicin—uterine cancer	0.00061	0.173	CbGdCrCtD
Nilotinib—HCK—vagina—uterine cancer	0.00061	0.0039	CbGeAlD
Nilotinib—ABL2—female gonad—uterine cancer	0.00061	0.0039	CbGeAlD
Nilotinib—ABL2—vagina—uterine cancer	0.000606	0.00387	CbGeAlD
Nilotinib—PDGFRA—smooth muscle tissue—uterine cancer	0.000602	0.00385	CbGeAlD
Nilotinib—EPHB4—uterus—uterine cancer	0.000596	0.00381	CbGeAlD
Nilotinib—EPHB6—endometrium—uterine cancer	0.000591	0.00378	CbGeAlD
Nilotinib—PDGFRA—decidua—uterine cancer	0.00059	0.00378	CbGeAlD
Nilotinib—MAPK11—lymph node—uterine cancer	0.00058	0.00371	CbGeAlD
Nilotinib—PDGFRA—renal system—uterine cancer	0.00058	0.00371	CbGeAlD
Nilotinib—CA9—female reproductive system—uterine cancer	0.000579	0.00371	CbGeAlD
Nilotinib—CDC42BPB—lymph node—uterine cancer	0.000575	0.00368	CbGeAlD
Nilotinib—EPHB6—mammalian vulva—uterine cancer	0.000572	0.00366	CbGeAlD
Nilotinib—TEK—uterus—uterine cancer	0.00057	0.00365	CbGeAlD
Nilotinib—MAPK14—female reproductive system—uterine cancer	0.000565	0.00361	CbGeAlD
Nilotinib—ABL1—Epirubicin—Doxorubicin—uterine cancer	0.000565	0.16	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Doxorubicin—uterine cancer	0.000565	0.16	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—uterine cancer	0.000565	0.16	CbGdCrCtD
Nilotinib—FGR—female reproductive system—uterine cancer	0.000563	0.0036	CbGeAlD
Nilotinib—MAP2K5—uterine cervix—uterine cancer	0.000559	0.00358	CbGeAlD
Nilotinib—EPHA4—female gonad—uterine cancer	0.000557	0.00357	CbGeAlD
Nilotinib—ABL1—myometrium—uterine cancer	0.000554	0.00354	CbGeAlD
Nilotinib—EPHA4—vagina—uterine cancer	0.000554	0.00354	CbGeAlD
Nilotinib—UGT1A1—renal system—uterine cancer	0.000553	0.00354	CbGeAlD
Nilotinib—CA3—vagina—uterine cancer	0.000547	0.0035	CbGeAlD
Nilotinib—CSF1R—uterine cervix—uterine cancer	0.000546	0.00349	CbGeAlD
Nilotinib—EPHA3—lymph node—uterine cancer	0.000545	0.00349	CbGeAlD
Nilotinib—EPHB4—female reproductive system—uterine cancer	0.000535	0.00342	CbGeAlD
Nilotinib—CA12—renal system—uterine cancer	0.000535	0.00342	CbGeAlD
Nilotinib—MAP2K5—decidua—uterine cancer	0.000533	0.00341	CbGeAlD
Nilotinib—CSF1R—smooth muscle tissue—uterine cancer	0.00053	0.00339	CbGeAlD
Nilotinib—EPHA2—female reproductive system—uterine cancer	0.000525	0.00336	CbGeAlD
Nilotinib—MAPK8—lymph node—uterine cancer	0.00052	0.00333	CbGeAlD
Nilotinib—CSF1R—decidua—uterine cancer	0.00052	0.00332	CbGeAlD
Nilotinib—PDGFRA—uterus—uterine cancer	0.000516	0.0033	CbGeAlD
Nilotinib—MAPK14—female gonad—uterine cancer	0.000514	0.00329	CbGeAlD
Nilotinib—TEK—female reproductive system—uterine cancer	0.000512	0.00328	CbGeAlD
Nilotinib—FGR—female gonad—uterine cancer	0.000512	0.00327	CbGeAlD
Nilotinib—LCK—female gonad—uterine cancer	0.000512	0.00327	CbGeAlD
Nilotinib—MAPK14—vagina—uterine cancer	0.000511	0.00327	CbGeAlD
Nilotinib—FGR—vagina—uterine cancer	0.000509	0.00325	CbGeAlD
Nilotinib—LCK—vagina—uterine cancer	0.000509	0.00325	CbGeAlD
Nilotinib—MAP2K5—endometrium—uterine cancer	0.000506	0.00323	CbGeAlD
Nilotinib—KIT—epithelium—uterine cancer	0.0005	0.0032	CbGeAlD
Nilotinib—KIT—uterine cervix—uterine cancer	0.000495	0.00317	CbGeAlD
Nilotinib—CSF1R—endometrium—uterine cancer	0.000493	0.00316	CbGeAlD
Nilotinib—MAP2K5—mammalian vulva—uterine cancer	0.000489	0.00313	CbGeAlD
Nilotinib—PDGFRB—epithelium—uterine cancer	0.000488	0.00312	CbGeAlD
Nilotinib—EPHB4—female gonad—uterine cancer	0.000487	0.00312	CbGeAlD
Nilotinib—EPHB4—vagina—uterine cancer	0.000484	0.0031	CbGeAlD
Nilotinib—PDGFRB—uterine cervix—uterine cancer	0.000484	0.00309	CbGeAlD
Nilotinib—KIT—smooth muscle tissue—uterine cancer	0.000481	0.00308	CbGeAlD
Nilotinib—EPHA2—female gonad—uterine cancer	0.000478	0.00306	CbGeAlD
Nilotinib—CSF1R—mammalian vulva—uterine cancer	0.000477	0.00305	CbGeAlD
Nilotinib—EPHA2—vagina—uterine cancer	0.000475	0.00304	CbGeAlD
Nilotinib—MAP4K1—lymph node—uterine cancer	0.000473	0.00302	CbGeAlD
Nilotinib—KIT—decidua—uterine cancer	0.000472	0.00302	CbGeAlD
Nilotinib—PDGFRB—smooth muscle tissue—uterine cancer	0.00047	0.00301	CbGeAlD
Nilotinib—TEK—female gonad—uterine cancer	0.000466	0.00298	CbGeAlD
Nilotinib—PDGFRA—female reproductive system—uterine cancer	0.000464	0.00297	CbGeAlD
Nilotinib—KIT—renal system—uterine cancer	0.000463	0.00296	CbGeAlD
Nilotinib—PDGFRB—decidua—uterine cancer	0.000461	0.00295	CbGeAlD
Nilotinib—CSF1R—uterus—uterine cancer	0.000455	0.00291	CbGeAlD
Nilotinib—PDGFRB—renal system—uterine cancer	0.000453	0.0029	CbGeAlD
Nilotinib—TIE1—lymph node—uterine cancer	0.000451	0.00289	CbGeAlD
Nilotinib—KIT—endometrium—uterine cancer	0.000448	0.00287	CbGeAlD
Nilotinib—EPHB6—female gonad—uterine cancer	0.000446	0.00285	CbGeAlD
Nilotinib—EPHB6—vagina—uterine cancer	0.000443	0.00283	CbGeAlD
Nilotinib—PDGFRB—endometrium—uterine cancer	0.000438	0.0028	CbGeAlD
Nilotinib—KIT—mammalian vulva—uterine cancer	0.000433	0.00277	CbGeAlD
Nilotinib—BRAF—lymph node—uterine cancer	0.000433	0.00277	CbGeAlD
Nilotinib—ABL1—uterine cervix—uterine cancer	0.000431	0.00276	CbGeAlD
Nilotinib—EPHB3—lymph node—uterine cancer	0.000429	0.00274	CbGeAlD
Nilotinib—CA12—female reproductive system—uterine cancer	0.000429	0.00274	CbGeAlD
Nilotinib—CA1—renal system—uterine cancer	0.000424	0.00271	CbGeAlD
Nilotinib—PDGFRB—mammalian vulva—uterine cancer	0.000423	0.00271	CbGeAlD
Nilotinib—PDGFRA—female gonad—uterine cancer	0.000422	0.0027	CbGeAlD
Nilotinib—PDGFRA—vagina—uterine cancer	0.00042	0.00269	CbGeAlD
Nilotinib—ABL1—smooth muscle tissue—uterine cancer	0.000419	0.00268	CbGeAlD
Nilotinib—MAP2K5—female reproductive system—uterine cancer	0.000419	0.00268	CbGeAlD
Nilotinib—KIT—uterus—uterine cancer	0.000413	0.00264	CbGeAlD
Nilotinib—ABL1—decidua—uterine cancer	0.000411	0.00263	CbGeAlD
Nilotinib—CSF1R—female reproductive system—uterine cancer	0.000409	0.00261	CbGeAlD
Nilotinib—ABL1—renal system—uterine cancer	0.000403	0.00258	CbGeAlD
Nilotinib—PDGFRB—uterus—uterine cancer	0.000403	0.00258	CbGeAlD
Nilotinib—HCK—lymph node—uterine cancer	0.000394	0.00252	CbGeAlD
Nilotinib—ABL2—lymph node—uterine cancer	0.000392	0.00251	CbGeAlD
Nilotinib—ABL1—endometrium—uterine cancer	0.00039	0.00249	CbGeAlD
Nilotinib—MAP2K5—female gonad—uterine cancer	0.000381	0.00244	CbGeAlD
Nilotinib—MAP2K5—vagina—uterine cancer	0.000379	0.00242	CbGeAlD
Nilotinib—ABL1—mammalian vulva—uterine cancer	0.000377	0.00241	CbGeAlD
Nilotinib—CSF1R—female gonad—uterine cancer	0.000372	0.00238	CbGeAlD
Nilotinib—KIT—female reproductive system—uterine cancer	0.000371	0.00237	CbGeAlD
Nilotinib—CSF1R—vagina—uterine cancer	0.00037	0.00236	CbGeAlD
Nilotinib—PDGFRB—female reproductive system—uterine cancer	0.000363	0.00232	CbGeAlD
Nilotinib—ABL1—uterus—uterine cancer	0.000359	0.0023	CbGeAlD
Nilotinib—EPHA4—lymph node—uterine cancer	0.000358	0.00229	CbGeAlD
Nilotinib—CA3—lymph node—uterine cancer	0.000354	0.00226	CbGeAlD
Nilotinib—ABCG2—myometrium—uterine cancer	0.000349	0.00224	CbGeAlD
Nilotinib—CA1—female reproductive system—uterine cancer	0.000339	0.00217	CbGeAlD
Nilotinib—KIT—female gonad—uterine cancer	0.000338	0.00216	CbGeAlD
Nilotinib—KIT—vagina—uterine cancer	0.000336	0.00215	CbGeAlD
Nilotinib—CA4—renal system—uterine cancer	0.000331	0.00212	CbGeAlD
Nilotinib—MAPK14—lymph node—uterine cancer	0.00033	0.00211	CbGeAlD
Nilotinib—PDGFRB—female gonad—uterine cancer	0.00033	0.00211	CbGeAlD
Nilotinib—LCK—lymph node—uterine cancer	0.000329	0.0021	CbGeAlD
Nilotinib—FGR—lymph node—uterine cancer	0.000329	0.0021	CbGeAlD
Nilotinib—PDGFRB—vagina—uterine cancer	0.000328	0.0021	CbGeAlD
Nilotinib—ABL1—female reproductive system—uterine cancer	0.000323	0.00207	CbGeAlD
Nilotinib—EPHB4—lymph node—uterine cancer	0.000313	0.002	CbGeAlD
Nilotinib—EPHA2—lymph node—uterine cancer	0.000307	0.00197	CbGeAlD
Nilotinib—TEK—lymph node—uterine cancer	0.0003	0.00192	CbGeAlD
Nilotinib—CA2—epithelium—uterine cancer	0.000296	0.00189	CbGeAlD
Nilotinib—ABL1—female gonad—uterine cancer	0.000294	0.00188	CbGeAlD
Nilotinib—ABL1—vagina—uterine cancer	0.000292	0.00187	CbGeAlD
Nilotinib—EPHB6—lymph node—uterine cancer	0.000287	0.00183	CbGeAlD
Nilotinib—CA2—smooth muscle tissue—uterine cancer	0.000285	0.00183	CbGeAlD
Nilotinib—CA2—decidua—uterine cancer	0.00028	0.00179	CbGeAlD
Nilotinib—CA2—renal system—uterine cancer	0.000275	0.00176	CbGeAlD
Nilotinib—ABCG2—uterine cervix—uterine cancer	0.000272	0.00174	CbGeAlD
Nilotinib—PDGFRA—lymph node—uterine cancer	0.000272	0.00174	CbGeAlD
Nilotinib—CA4—female reproductive system—uterine cancer	0.000265	0.0017	CbGeAlD
Nilotinib—CYP2C8—renal system—uterine cancer	0.000262	0.00167	CbGeAlD
Nilotinib—ABCG2—decidua—uterine cancer	0.000259	0.00166	CbGeAlD
Nilotinib—CA2—mammalian vulva—uterine cancer	0.000257	0.00164	CbGeAlD
Nilotinib—CYP2C8—endometrium—uterine cancer	0.000253	0.00162	CbGeAlD
Nilotinib—ABCG2—endometrium—uterine cancer	0.000246	0.00157	CbGeAlD
Nilotinib—MAP2K5—lymph node—uterine cancer	0.000245	0.00157	CbGeAlD
Nilotinib—CA4—female gonad—uterine cancer	0.000241	0.00154	CbGeAlD
Nilotinib—CSF1R—lymph node—uterine cancer	0.000239	0.00153	CbGeAlD
Nilotinib—ABCG2—mammalian vulva—uterine cancer	0.000238	0.00152	CbGeAlD
Nilotinib—CYP2B6—renal system—uterine cancer	0.000235	0.0015	CbGeAlD
Nilotinib—ABCG2—uterus—uterine cancer	0.000227	0.00145	CbGeAlD
Nilotinib—CA2—female reproductive system—uterine cancer	0.00022	0.00141	CbGeAlD
Nilotinib—KIT—lymph node—uterine cancer	0.000217	0.00139	CbGeAlD
Nilotinib—PDGFRB—lymph node—uterine cancer	0.000212	0.00136	CbGeAlD
Nilotinib—CYP2C8—female reproductive system—uterine cancer	0.00021	0.00134	CbGeAlD
Nilotinib—CA2—female gonad—uterine cancer	0.0002	0.00128	CbGeAlD
Nilotinib—CA2—vagina—uterine cancer	0.000199	0.00127	CbGeAlD
Nilotinib—CA1—lymph node—uterine cancer	0.000199	0.00127	CbGeAlD
Nilotinib—CYP2C8—vagina—uterine cancer	0.00019	0.00121	CbGeAlD
Nilotinib—ABL1—lymph node—uterine cancer	0.000189	0.00121	CbGeAlD
Nilotinib—CYP2B6—female reproductive system—uterine cancer	0.000188	0.0012	CbGeAlD
Nilotinib—CYP2C9—female reproductive system—uterine cancer	0.000186	0.00119	CbGeAlD
Nilotinib—ABCG2—female gonad—uterine cancer	0.000185	0.00119	CbGeAlD
Nilotinib—ABCG2—vagina—uterine cancer	0.000184	0.00118	CbGeAlD
Nilotinib—CYP3A4—renal system—uterine cancer	0.000177	0.00113	CbGeAlD
Nilotinib—CYP2D6—renal system—uterine cancer	0.000174	0.00112	CbGeAlD
Nilotinib—ABCB1—myometrium—uterine cancer	0.000172	0.0011	CbGeAlD
Nilotinib—CYP2B6—vagina—uterine cancer	0.00017	0.00109	CbGeAlD
Nilotinib—CA4—lymph node—uterine cancer	0.000155	0.000993	CbGeAlD
Nilotinib—CYP3A4—female reproductive system—uterine cancer	0.000142	0.000908	CbGeAlD
Nilotinib—CYP2D6—female reproductive system—uterine cancer	0.00014	0.000893	CbGeAlD
Nilotinib—ABCB1—epithelium—uterine cancer	0.000135	0.000865	CbGeAlD
Nilotinib—ABCB1—uterine cervix—uterine cancer	0.000134	0.000858	CbGeAlD
Nilotinib—CA2—lymph node—uterine cancer	0.000129	0.000823	CbGeAlD
Nilotinib—ABCB1—decidua—uterine cancer	0.000128	0.000817	CbGeAlD
Nilotinib—CYP2D6—female gonad—uterine cancer	0.000127	0.000813	CbGeAlD
Nilotinib—ABCB1—renal system—uterine cancer	0.000125	0.000802	CbGeAlD
Nilotinib—ABCB1—endometrium—uterine cancer	0.000121	0.000776	CbGeAlD
Nilotinib—ABCG2—lymph node—uterine cancer	0.000119	0.000762	CbGeAlD
Nilotinib—ABCB1—mammalian vulva—uterine cancer	0.000117	0.00075	CbGeAlD
Nilotinib—Anorexia—Etoposide—uterine cancer	0.000115	0.000529	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000115	0.000528	CcSEcCtD
Nilotinib—Bronchitis—Epirubicin—uterine cancer	0.000115	0.000526	CcSEcCtD
Nilotinib—Diarrhoea—Dactinomycin—uterine cancer	0.000114	0.000525	CcSEcCtD
Nilotinib—Nasopharyngitis—Doxorubicin—uterine cancer	0.000114	0.000524	CcSEcCtD
Nilotinib—Pancytopenia—Epirubicin—uterine cancer	0.000113	0.00052	CcSEcCtD
Nilotinib—Hypotension—Etoposide—uterine cancer	0.000113	0.000519	CcSEcCtD
Nilotinib—Gastritis—Doxorubicin—uterine cancer	0.000113	0.000518	CcSEcCtD
Nilotinib—Muscular weakness—Doxorubicin—uterine cancer	0.000112	0.000517	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000112	0.000517	CcSEcCtD
Nilotinib—ABCB1—uterus—uterine cancer	0.000112	0.000715	CbGeAlD
Nilotinib—Dysuria—Epirubicin—uterine cancer	0.000111	0.000512	CcSEcCtD
Nilotinib—Neutropenia—Epirubicin—uterine cancer	0.000111	0.000512	CcSEcCtD
Nilotinib—Abdominal distension—Doxorubicin—uterine cancer	0.000111	0.00051	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000111	0.000509	CcSEcCtD
Nilotinib—Influenza—Doxorubicin—uterine cancer	0.00011	0.000506	CcSEcCtD
Nilotinib—Pollakiuria—Epirubicin—uterine cancer	0.00011	0.000506	CcSEcCtD
Nilotinib—Eosinophilia—Doxorubicin—uterine cancer	0.000109	0.000501	CcSEcCtD
Nilotinib—Photosensitivity reaction—Epirubicin—uterine cancer	0.000109	0.000499	CcSEcCtD
Nilotinib—Paraesthesia—Etoposide—uterine cancer	0.000108	0.000498	CcSEcCtD
Nilotinib—Weight increased—Epirubicin—uterine cancer	0.000108	0.000498	CcSEcCtD
Nilotinib—Pancreatitis—Doxorubicin—uterine cancer	0.000108	0.000496	CcSEcCtD
Nilotinib—Weight decreased—Epirubicin—uterine cancer	0.000108	0.000495	CcSEcCtD
Nilotinib—Dyspnoea—Etoposide—uterine cancer	0.000108	0.000495	CcSEcCtD
Nilotinib—Hyperglycaemia—Epirubicin—uterine cancer	0.000107	0.000494	CcSEcCtD
Nilotinib—Angina pectoris—Doxorubicin—uterine cancer	0.000107	0.000493	CcSEcCtD
Nilotinib—Pneumonia—Epirubicin—uterine cancer	0.000107	0.000491	CcSEcCtD
Nilotinib—Infestation NOS—Epirubicin—uterine cancer	0.000106	0.000488	CcSEcCtD
Nilotinib—Infestation—Epirubicin—uterine cancer	0.000106	0.000488	CcSEcCtD
Nilotinib—Vomiting—Dactinomycin—uterine cancer	0.000106	0.000488	CcSEcCtD
Nilotinib—Bronchitis—Doxorubicin—uterine cancer	0.000106	0.000487	CcSEcCtD
Nilotinib—Rash—Dactinomycin—uterine cancer	0.000105	0.000484	CcSEcCtD
Nilotinib—Decreased appetite—Etoposide—uterine cancer	0.000105	0.000483	CcSEcCtD
Nilotinib—Pancytopenia—Doxorubicin—uterine cancer	0.000105	0.000481	CcSEcCtD
Nilotinib—Renal failure—Epirubicin—uterine cancer	0.000104	0.00048	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000104	0.000479	CcSEcCtD
Nilotinib—Fatigue—Etoposide—uterine cancer	0.000104	0.000479	CcSEcCtD
Nilotinib—Neuropathy peripheral—Epirubicin—uterine cancer	0.000104	0.000478	CcSEcCtD
Nilotinib—Stomatitis—Epirubicin—uterine cancer	0.000103	0.000476	CcSEcCtD
Nilotinib—Jaundice—Epirubicin—uterine cancer	0.000103	0.000476	CcSEcCtD
Nilotinib—Pain—Etoposide—uterine cancer	0.000103	0.000475	CcSEcCtD
Nilotinib—Constipation—Etoposide—uterine cancer	0.000103	0.000475	CcSEcCtD
Nilotinib—Conjunctivitis—Epirubicin—uterine cancer	0.000103	0.000474	CcSEcCtD
Nilotinib—Urinary tract infection—Epirubicin—uterine cancer	0.000103	0.000474	CcSEcCtD
Nilotinib—Neutropenia—Doxorubicin—uterine cancer	0.000103	0.000473	CcSEcCtD
Nilotinib—Dysuria—Doxorubicin—uterine cancer	0.000103	0.000473	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000102	0.000471	CcSEcCtD
Nilotinib—Pollakiuria—Doxorubicin—uterine cancer	0.000102	0.000468	CcSEcCtD
Nilotinib—Haematuria—Epirubicin—uterine cancer	0.000101	0.000465	CcSEcCtD
Nilotinib—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000101	0.000462	CcSEcCtD
Nilotinib—ABCB1—female reproductive system—uterine cancer	0.0001	0.000643	CbGeAlD
Nilotinib—Hepatobiliary disease—Epirubicin—uterine cancer	0.0001	0.000461	CcSEcCtD
Nilotinib—Weight increased—Doxorubicin—uterine cancer	0.0001	0.000461	CcSEcCtD
Nilotinib—Epistaxis—Epirubicin—uterine cancer	0.0001	0.00046	CcSEcCtD
Nilotinib—Weight decreased—Doxorubicin—uterine cancer	9.97e-05	0.000458	CcSEcCtD
Nilotinib—Feeling abnormal—Etoposide—uterine cancer	9.95e-05	0.000457	CcSEcCtD
Nilotinib—Hyperglycaemia—Doxorubicin—uterine cancer	9.94e-05	0.000457	CcSEcCtD
Nilotinib—Nausea—Dactinomycin—uterine cancer	9.91e-05	0.000456	CcSEcCtD
Nilotinib—Pneumonia—Doxorubicin—uterine cancer	9.88e-05	0.000454	CcSEcCtD
Nilotinib—Gastrointestinal pain—Etoposide—uterine cancer	9.88e-05	0.000454	CcSEcCtD
Nilotinib—Infestation—Doxorubicin—uterine cancer	9.82e-05	0.000451	CcSEcCtD
Nilotinib—Infestation NOS—Doxorubicin—uterine cancer	9.82e-05	0.000451	CcSEcCtD
Nilotinib—Bradycardia—Epirubicin—uterine cancer	9.7e-05	0.000446	CcSEcCtD
Nilotinib—Renal failure—Doxorubicin—uterine cancer	9.66e-05	0.000444	CcSEcCtD
Nilotinib—Neuropathy peripheral—Doxorubicin—uterine cancer	9.63e-05	0.000443	CcSEcCtD
Nilotinib—Urticaria—Etoposide—uterine cancer	9.6e-05	0.000441	CcSEcCtD
Nilotinib—Haemoglobin—Epirubicin—uterine cancer	9.58e-05	0.00044	CcSEcCtD
Nilotinib—Jaundice—Doxorubicin—uterine cancer	9.58e-05	0.00044	CcSEcCtD
Nilotinib—Stomatitis—Doxorubicin—uterine cancer	9.58e-05	0.00044	CcSEcCtD
Nilotinib—Rhinitis—Epirubicin—uterine cancer	9.56e-05	0.000439	CcSEcCtD
Nilotinib—Abdominal pain—Etoposide—uterine cancer	9.55e-05	0.000439	CcSEcCtD
Nilotinib—Body temperature increased—Etoposide—uterine cancer	9.55e-05	0.000439	CcSEcCtD
Nilotinib—Urinary tract infection—Doxorubicin—uterine cancer	9.55e-05	0.000439	CcSEcCtD
Nilotinib—Conjunctivitis—Doxorubicin—uterine cancer	9.55e-05	0.000439	CcSEcCtD
Nilotinib—Hepatitis—Epirubicin—uterine cancer	9.53e-05	0.000438	CcSEcCtD
Nilotinib—Haemorrhage—Epirubicin—uterine cancer	9.53e-05	0.000438	CcSEcCtD
Nilotinib—Hypoaesthesia—Epirubicin—uterine cancer	9.48e-05	0.000436	CcSEcCtD
Nilotinib—Pharyngitis—Epirubicin—uterine cancer	9.46e-05	0.000435	CcSEcCtD
Nilotinib—Urinary tract disorder—Epirubicin—uterine cancer	9.41e-05	0.000433	CcSEcCtD
Nilotinib—Oedema peripheral—Epirubicin—uterine cancer	9.39e-05	0.000431	CcSEcCtD
Nilotinib—Haematuria—Doxorubicin—uterine cancer	9.37e-05	0.00043	CcSEcCtD
Nilotinib—Connective tissue disorder—Epirubicin—uterine cancer	9.37e-05	0.00043	CcSEcCtD
Nilotinib—Urethral disorder—Epirubicin—uterine cancer	9.34e-05	0.000429	CcSEcCtD
Nilotinib—Hepatobiliary disease—Doxorubicin—uterine cancer	9.29e-05	0.000427	CcSEcCtD
Nilotinib—Epistaxis—Doxorubicin—uterine cancer	9.27e-05	0.000426	CcSEcCtD
Nilotinib—Visual impairment—Epirubicin—uterine cancer	9.19e-05	0.000422	CcSEcCtD
Nilotinib—ABCB1—female gonad—uterine cancer	9.14e-05	0.000585	CbGeAlD
Nilotinib—ABCB1—vagina—uterine cancer	9.09e-05	0.000581	CbGeAlD
Nilotinib—Erythema multiforme—Epirubicin—uterine cancer	9.01e-05	0.000414	CcSEcCtD
Nilotinib—Bradycardia—Doxorubicin—uterine cancer	8.98e-05	0.000413	CcSEcCtD
Nilotinib—Eye disorder—Epirubicin—uterine cancer	8.91e-05	0.000409	CcSEcCtD
Nilotinib—Hypersensitivity—Etoposide—uterine cancer	8.9e-05	0.000409	CcSEcCtD
Nilotinib—Tinnitus—Epirubicin—uterine cancer	8.89e-05	0.000408	CcSEcCtD
Nilotinib—Haemoglobin—Doxorubicin—uterine cancer	8.86e-05	0.000407	CcSEcCtD
Nilotinib—Flushing—Epirubicin—uterine cancer	8.85e-05	0.000407	CcSEcCtD
Nilotinib—Cardiac disorder—Epirubicin—uterine cancer	8.85e-05	0.000407	CcSEcCtD
Nilotinib—Rhinitis—Doxorubicin—uterine cancer	8.84e-05	0.000406	CcSEcCtD
Nilotinib—Haemorrhage—Doxorubicin—uterine cancer	8.82e-05	0.000405	CcSEcCtD
Nilotinib—Hepatitis—Doxorubicin—uterine cancer	8.82e-05	0.000405	CcSEcCtD
Nilotinib—Hypoaesthesia—Doxorubicin—uterine cancer	8.77e-05	0.000403	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—uterine cancer	8.75e-05	0.000402	CcSEcCtD
Nilotinib—Urinary tract disorder—Doxorubicin—uterine cancer	8.71e-05	0.0004	CcSEcCtD
Nilotinib—Oedema peripheral—Doxorubicin—uterine cancer	8.69e-05	0.000399	CcSEcCtD
Nilotinib—Asthenia—Etoposide—uterine cancer	8.67e-05	0.000398	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—uterine cancer	8.67e-05	0.000398	CcSEcCtD
Nilotinib—Angiopathy—Epirubicin—uterine cancer	8.65e-05	0.000397	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—uterine cancer	8.64e-05	0.000397	CcSEcCtD
Nilotinib—Immune system disorder—Epirubicin—uterine cancer	8.61e-05	0.000396	CcSEcCtD
Nilotinib—Mediastinal disorder—Epirubicin—uterine cancer	8.59e-05	0.000395	CcSEcCtD
Nilotinib—Chills—Epirubicin—uterine cancer	8.55e-05	0.000393	CcSEcCtD
Nilotinib—Pruritus—Etoposide—uterine cancer	8.55e-05	0.000393	CcSEcCtD
Nilotinib—Arrhythmia—Epirubicin—uterine cancer	8.51e-05	0.000391	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—uterine cancer	8.5e-05	0.000391	CcSEcCtD
Nilotinib—Alopecia—Epirubicin—uterine cancer	8.42e-05	0.000387	CcSEcCtD
Nilotinib—Mental disorder—Epirubicin—uterine cancer	8.35e-05	0.000384	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—uterine cancer	8.34e-05	0.000383	CcSEcCtD
Nilotinib—Erythema—Epirubicin—uterine cancer	8.3e-05	0.000381	CcSEcCtD
Nilotinib—Malnutrition—Epirubicin—uterine cancer	8.3e-05	0.000381	CcSEcCtD
Nilotinib—Diarrhoea—Etoposide—uterine cancer	8.27e-05	0.00038	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—uterine cancer	8.24e-05	0.000379	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—uterine cancer	8.22e-05	0.000378	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—uterine cancer	8.18e-05	0.000376	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—uterine cancer	8.18e-05	0.000376	CcSEcCtD
Nilotinib—Flatulence—Epirubicin—uterine cancer	8.18e-05	0.000376	CcSEcCtD
Nilotinib—Dysgeusia—Epirubicin—uterine cancer	8.13e-05	0.000373	CcSEcCtD
Nilotinib—Back pain—Epirubicin—uterine cancer	8.03e-05	0.000369	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—uterine cancer	8e-05	0.000368	CcSEcCtD
Nilotinib—Dizziness—Etoposide—uterine cancer	7.99e-05	0.000367	CcSEcCtD
Nilotinib—Muscle spasms—Epirubicin—uterine cancer	7.98e-05	0.000367	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—uterine cancer	7.97e-05	0.000366	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—uterine cancer	7.95e-05	0.000365	CcSEcCtD
Nilotinib—Chills—Doxorubicin—uterine cancer	7.91e-05	0.000364	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—uterine cancer	7.88e-05	0.000362	CcSEcCtD
Nilotinib—Vision blurred—Epirubicin—uterine cancer	7.82e-05	0.000359	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—uterine cancer	7.79e-05	0.000358	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—uterine cancer	7.73e-05	0.000355	CcSEcCtD
Nilotinib—Ill-defined disorder—Epirubicin—uterine cancer	7.7e-05	0.000354	CcSEcCtD
Nilotinib—Vomiting—Etoposide—uterine cancer	7.68e-05	0.000353	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—uterine cancer	7.68e-05	0.000353	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—uterine cancer	7.68e-05	0.000353	CcSEcCtD
Nilotinib—Anaemia—Epirubicin—uterine cancer	7.67e-05	0.000352	CcSEcCtD
Nilotinib—Rash—Etoposide—uterine cancer	7.62e-05	0.00035	CcSEcCtD
Nilotinib—Dermatitis—Etoposide—uterine cancer	7.61e-05	0.00035	CcSEcCtD
Nilotinib—Headache—Etoposide—uterine cancer	7.57e-05	0.000348	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—uterine cancer	7.56e-05	0.000348	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—uterine cancer	7.52e-05	0.000345	CcSEcCtD
Nilotinib—Malaise—Epirubicin—uterine cancer	7.48e-05	0.000344	CcSEcCtD
Nilotinib—Vertigo—Epirubicin—uterine cancer	7.45e-05	0.000343	CcSEcCtD
Nilotinib—Syncope—Epirubicin—uterine cancer	7.44e-05	0.000342	CcSEcCtD
Nilotinib—Leukopenia—Epirubicin—uterine cancer	7.43e-05	0.000341	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—uterine cancer	7.43e-05	0.000341	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—uterine cancer	7.38e-05	0.000339	CcSEcCtD
Nilotinib—Palpitations—Epirubicin—uterine cancer	7.33e-05	0.000337	CcSEcCtD
Nilotinib—Loss of consciousness—Epirubicin—uterine cancer	7.29e-05	0.000335	CcSEcCtD
Nilotinib—Cough—Epirubicin—uterine cancer	7.24e-05	0.000333	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—uterine cancer	7.24e-05	0.000332	CcSEcCtD
Nilotinib—Nausea—Etoposide—uterine cancer	7.18e-05	0.00033	CcSEcCtD
Nilotinib—Hypertension—Epirubicin—uterine cancer	7.16e-05	0.000329	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—uterine cancer	7.12e-05	0.000327	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—uterine cancer	7.1e-05	0.000326	CcSEcCtD
Nilotinib—Chest pain—Epirubicin—uterine cancer	7.06e-05	0.000325	CcSEcCtD
Nilotinib—Arthralgia—Epirubicin—uterine cancer	7.06e-05	0.000325	CcSEcCtD
Nilotinib—Myalgia—Epirubicin—uterine cancer	7.06e-05	0.000325	CcSEcCtD
Nilotinib—Anxiety—Epirubicin—uterine cancer	7.04e-05	0.000323	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	7.02e-05	0.000322	CcSEcCtD
Nilotinib—Discomfort—Epirubicin—uterine cancer	6.98e-05	0.000321	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—uterine cancer	6.92e-05	0.000318	CcSEcCtD
Nilotinib—Dry mouth—Epirubicin—uterine cancer	6.91e-05	0.000317	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—uterine cancer	6.9e-05	0.000317	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—uterine cancer	6.88e-05	0.000316	CcSEcCtD
Nilotinib—Leukopenia—Doxorubicin—uterine cancer	6.87e-05	0.000316	CcSEcCtD
Nilotinib—Confusional state—Epirubicin—uterine cancer	6.83e-05	0.000314	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—uterine cancer	6.78e-05	0.000312	CcSEcCtD
Nilotinib—Oedema—Epirubicin—uterine cancer	6.77e-05	0.000311	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—uterine cancer	6.75e-05	0.00031	CcSEcCtD
Nilotinib—Infection—Epirubicin—uterine cancer	6.73e-05	0.000309	CcSEcCtD
Nilotinib—Cough—Doxorubicin—uterine cancer	6.7e-05	0.000308	CcSEcCtD
Nilotinib—Shock—Epirubicin—uterine cancer	6.66e-05	0.000306	CcSEcCtD
Nilotinib—Nervous system disorder—Epirubicin—uterine cancer	6.64e-05	0.000305	CcSEcCtD
Nilotinib—Thrombocytopenia—Epirubicin—uterine cancer	6.63e-05	0.000305	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—uterine cancer	6.63e-05	0.000305	CcSEcCtD
Nilotinib—Tachycardia—Epirubicin—uterine cancer	6.61e-05	0.000304	CcSEcCtD
Nilotinib—Skin disorder—Epirubicin—uterine cancer	6.58e-05	0.000302	CcSEcCtD
Nilotinib—Hyperhidrosis—Epirubicin—uterine cancer	6.55e-05	0.000301	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—uterine cancer	6.54e-05	0.0003	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—uterine cancer	6.54e-05	0.0003	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—uterine cancer	6.54e-05	0.0003	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—uterine cancer	6.51e-05	0.000299	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	6.49e-05	0.000298	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—uterine cancer	6.46e-05	0.000297	CcSEcCtD
Nilotinib—Anorexia—Epirubicin—uterine cancer	6.45e-05	0.000297	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—uterine cancer	6.39e-05	0.000294	CcSEcCtD
Nilotinib—Hypotension—Epirubicin—uterine cancer	6.33e-05	0.000291	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—uterine cancer	6.32e-05	0.00029	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—uterine cancer	6.27e-05	0.000288	CcSEcCtD
Nilotinib—Infection—Doxorubicin—uterine cancer	6.22e-05	0.000286	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Epirubicin—uterine cancer	6.17e-05	0.000284	CcSEcCtD
Nilotinib—Shock—Doxorubicin—uterine cancer	6.16e-05	0.000283	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—uterine cancer	6.14e-05	0.000282	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—uterine cancer	6.13e-05	0.000282	CcSEcCtD
Nilotinib—Insomnia—Epirubicin—uterine cancer	6.12e-05	0.000281	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—uterine cancer	6.12e-05	0.000281	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—uterine cancer	6.09e-05	0.00028	CcSEcCtD
Nilotinib—Paraesthesia—Epirubicin—uterine cancer	6.08e-05	0.000279	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—uterine cancer	6.06e-05	0.000278	CcSEcCtD
Nilotinib—Dyspnoea—Epirubicin—uterine cancer	6.04e-05	0.000277	CcSEcCtD
Nilotinib—Anorexia—Doxorubicin—uterine cancer	5.97e-05	0.000274	CcSEcCtD
Nilotinib—Dyspepsia—Epirubicin—uterine cancer	5.96e-05	0.000274	CcSEcCtD
Nilotinib—Decreased appetite—Epirubicin—uterine cancer	5.89e-05	0.000271	CcSEcCtD
Nilotinib—ABCB1—lymph node—uterine cancer	5.88e-05	0.000376	CbGeAlD
Nilotinib—Hypotension—Doxorubicin—uterine cancer	5.85e-05	0.000269	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Epirubicin—uterine cancer	5.85e-05	0.000269	CcSEcCtD
Nilotinib—Fatigue—Epirubicin—uterine cancer	5.84e-05	0.000268	CcSEcCtD
Nilotinib—Pain—Epirubicin—uterine cancer	5.79e-05	0.000266	CcSEcCtD
Nilotinib—Constipation—Epirubicin—uterine cancer	5.79e-05	0.000266	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.71e-05	0.000262	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—uterine cancer	5.67e-05	0.00026	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—uterine cancer	5.63e-05	0.000259	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—uterine cancer	5.59e-05	0.000257	CcSEcCtD
Nilotinib—Feeling abnormal—Epirubicin—uterine cancer	5.58e-05	0.000256	CcSEcCtD
Nilotinib—Gastrointestinal pain—Epirubicin—uterine cancer	5.54e-05	0.000254	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—uterine cancer	5.52e-05	0.000253	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—uterine cancer	5.45e-05	0.00025	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—uterine cancer	5.41e-05	0.000249	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—uterine cancer	5.4e-05	0.000248	CcSEcCtD
Nilotinib—Urticaria—Epirubicin—uterine cancer	5.38e-05	0.000247	CcSEcCtD
Nilotinib—Pain—Doxorubicin—uterine cancer	5.36e-05	0.000246	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—uterine cancer	5.36e-05	0.000246	CcSEcCtD
Nilotinib—Body temperature increased—Epirubicin—uterine cancer	5.35e-05	0.000246	CcSEcCtD
Nilotinib—Abdominal pain—Epirubicin—uterine cancer	5.35e-05	0.000246	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—uterine cancer	5.16e-05	0.000237	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—uterine cancer	5.12e-05	0.000235	CcSEcCtD
Nilotinib—Hypersensitivity—Epirubicin—uterine cancer	4.99e-05	0.000229	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—uterine cancer	4.98e-05	0.000229	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—uterine cancer	4.95e-05	0.000228	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—uterine cancer	4.95e-05	0.000228	CcSEcCtD
Nilotinib—Asthenia—Epirubicin—uterine cancer	4.86e-05	0.000223	CcSEcCtD
Nilotinib—Pruritus—Epirubicin—uterine cancer	4.79e-05	0.00022	CcSEcCtD
Nilotinib—Diarrhoea—Epirubicin—uterine cancer	4.63e-05	0.000213	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—uterine cancer	4.62e-05	0.000212	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—uterine cancer	4.5e-05	0.000207	CcSEcCtD
Nilotinib—Dizziness—Epirubicin—uterine cancer	4.48e-05	0.000206	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—uterine cancer	4.43e-05	0.000204	CcSEcCtD
Nilotinib—Vomiting—Epirubicin—uterine cancer	4.31e-05	0.000198	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—uterine cancer	4.29e-05	0.000197	CcSEcCtD
Nilotinib—Rash—Epirubicin—uterine cancer	4.27e-05	0.000196	CcSEcCtD
Nilotinib—Dermatitis—Epirubicin—uterine cancer	4.27e-05	0.000196	CcSEcCtD
Nilotinib—Headache—Epirubicin—uterine cancer	4.24e-05	0.000195	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—uterine cancer	4.14e-05	0.00019	CcSEcCtD
Nilotinib—Nausea—Epirubicin—uterine cancer	4.02e-05	0.000185	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—uterine cancer	3.98e-05	0.000183	CcSEcCtD
Nilotinib—Rash—Doxorubicin—uterine cancer	3.95e-05	0.000182	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—uterine cancer	3.95e-05	0.000181	CcSEcCtD
Nilotinib—Headache—Doxorubicin—uterine cancer	3.93e-05	0.00018	CcSEcCtD
Nilotinib—Nausea—Doxorubicin—uterine cancer	3.72e-05	0.000171	CcSEcCtD
Nilotinib—MAP2K5—Signaling Pathways—NRAS—uterine cancer	4.67e-06	2.25e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—STK11—uterine cancer	4.65e-06	2.24e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP19A1—uterine cancer	4.65e-06	2.24e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NRAS—uterine cancer	4.65e-06	2.24e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCL2—uterine cancer	4.64e-06	2.23e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ERBB2—uterine cancer	4.63e-06	2.23e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EP300—uterine cancer	4.61e-06	2.22e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—AKT1—uterine cancer	4.6e-06	2.21e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EP300—uterine cancer	4.59e-06	2.21e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—NRAS—uterine cancer	4.55e-06	2.19e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CDKN1B—uterine cancer	4.54e-06	2.19e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NRAS—uterine cancer	4.53e-06	2.18e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—ERBB2—uterine cancer	4.53e-06	2.18e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HRAS—uterine cancer	4.5e-06	2.17e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CTNNB1—uterine cancer	4.5e-06	2.16e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CTNNB1—uterine cancer	4.45e-06	2.14e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—POLD1—uterine cancer	4.45e-06	2.14e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KRAS—uterine cancer	4.44e-06	2.14e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HRAS—uterine cancer	4.42e-06	2.13e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AKT1—uterine cancer	4.42e-06	2.13e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCL2—uterine cancer	4.4e-06	2.12e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCL8—uterine cancer	4.39e-06	2.11e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ERBB2—uterine cancer	4.39e-06	2.11e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PTEN—uterine cancer	4.38e-06	2.11e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—PIK3CA—uterine cancer	4.37e-06	2.1e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PIK3CA—uterine cancer	4.37e-06	2.1e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.37e-06	2.1e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PTEN—uterine cancer	4.34e-06	2.09e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—KRAS—uterine cancer	4.33e-06	2.09e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ESR1—uterine cancer	4.32e-06	2.08e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NRAS—uterine cancer	4.32e-06	2.08e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—PIK3CA—uterine cancer	4.31e-06	2.07e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NRAS—uterine cancer	4.29e-06	2.07e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CDKN1B—uterine cancer	4.29e-06	2.07e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CTNNB1—uterine cancer	4.29e-06	2.07e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AKT1—uterine cancer	4.24e-06	2.04e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KRAS—uterine cancer	4.22e-06	2.03e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CDKN1B—uterine cancer	4.19e-06	2.02e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—PTEN—uterine cancer	4.18e-06	2.01e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EP300—uterine cancer	4.18e-06	2.01e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.16e-06	2e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKR1C1—uterine cancer	4.16e-06	2e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCL8—uterine cancer	4.16e-06	2e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EP300—uterine cancer	4.14e-06	1.99e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—AKT1—uterine cancer	4.14e-06	1.99e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MTHFR—uterine cancer	4.13e-06	1.99e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KRAS—uterine cancer	4.1e-06	1.97e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—PIK3CA—uterine cancer	4.08e-06	1.96e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AKT1—uterine cancer	4.06e-06	1.96e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDKN1B—uterine cancer	4.06e-06	1.95e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CTNNB1—uterine cancer	4.05e-06	1.95e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP19A1—uterine cancer	4.05e-06	1.95e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—STK11—uterine cancer	4.05e-06	1.95e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—HRAS—uterine cancer	4.05e-06	1.95e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KRAS—uterine cancer	4.02e-06	1.93e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KRAS—uterine cancer	4e-06	1.93e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—HRAS—uterine cancer	3.99e-06	1.92e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EP300—uterine cancer	3.99e-06	1.92e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PIK3CA—uterine cancer	3.98e-06	1.92e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—AKT1—uterine cancer	3.97e-06	1.91e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CTNNB1—uterine cancer	3.96e-06	1.91e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—uterine cancer	3.96e-06	1.9e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ERBB2—uterine cancer	3.95e-06	1.9e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PTEN—uterine cancer	3.95e-06	1.9e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—uterine cancer	3.92e-06	1.89e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—KRAS—uterine cancer	3.92e-06	1.89e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NRAS—uterine cancer	3.91e-06	1.88e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—AKT1—uterine cancer	3.91e-06	1.88e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KRAS—uterine cancer	3.9e-06	1.88e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—AKT1—uterine cancer	3.88e-06	1.87e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PIK3CA—uterine cancer	3.88e-06	1.87e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NRAS—uterine cancer	3.87e-06	1.86e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB2—uterine cancer	3.87e-06	1.86e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTEN—uterine cancer	3.86e-06	1.86e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CTNNB1—uterine cancer	3.84e-06	1.85e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—STK11—uterine cancer	3.82e-06	1.84e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP19A1—uterine cancer	3.82e-06	1.84e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL2—uterine cancer	3.8e-06	1.83e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP19A1—uterine cancer	3.79e-06	1.82e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—STK11—uterine cancer	3.79e-06	1.82e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HRAS—uterine cancer	3.78e-06	1.82e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EP300—uterine cancer	3.77e-06	1.81e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PIK3CA—uterine cancer	3.77e-06	1.81e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—uterine cancer	3.75e-06	1.81e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL8—uterine cancer	3.75e-06	1.8e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTEN—uterine cancer	3.74e-06	1.8e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NRAS—uterine cancer	3.73e-06	1.8e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KRAS—uterine cancer	3.72e-06	1.79e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—RRM2—uterine cancer	3.71e-06	1.79e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KRAS—uterine cancer	3.7e-06	1.78e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTEN—uterine cancer	3.69e-06	1.78e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PIK3CA—uterine cancer	3.69e-06	1.78e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—HRAS—uterine cancer	3.68e-06	1.77e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EP300—uterine cancer	3.68e-06	1.77e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PIK3CA—uterine cancer	3.68e-06	1.77e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL8—uterine cancer	3.67e-06	1.77e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB2—uterine cancer	3.67e-06	1.77e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1B—uterine cancer	3.66e-06	1.76e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—DCN—uterine cancer	3.6e-06	1.73e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—PIK3CA—uterine cancer	3.6e-06	1.73e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—uterine cancer	3.59e-06	1.73e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PIK3CA—uterine cancer	3.58e-06	1.72e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1B—uterine cancer	3.58e-06	1.72e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—uterine cancer	3.57e-06	1.72e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—uterine cancer	3.57e-06	1.72e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—uterine cancer	3.57e-06	1.72e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—uterine cancer	3.57e-06	1.72e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EP300—uterine cancer	3.57e-06	1.72e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.55e-06	1.71e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NRAS—uterine cancer	3.53e-06	1.7e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—uterine cancer	3.52e-06	1.7e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—EP300—uterine cancer	3.52e-06	1.69e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTHFR—uterine cancer	3.5e-06	1.68e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—uterine cancer	3.49e-06	1.68e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—uterine cancer	3.48e-06	1.67e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CTNNB1—uterine cancer	3.46e-06	1.66e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NRAS—uterine cancer	3.45e-06	1.66e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—uterine cancer	3.41e-06	1.64e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—uterine cancer	3.41e-06	1.64e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—uterine cancer	3.4e-06	1.64e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1B—uterine cancer	3.4e-06	1.63e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—uterine cancer	3.4e-06	1.63e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP11A1—uterine cancer	3.39e-06	1.63e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.39e-06	1.63e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CTNNB1—uterine cancer	3.39e-06	1.63e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—uterine cancer	3.38e-06	1.63e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTEN—uterine cancer	3.37e-06	1.62e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—uterine cancer	3.37e-06	1.62e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NRAS—uterine cancer	3.34e-06	1.61e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—uterine cancer	3.33e-06	1.6e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—uterine cancer	3.33e-06	1.6e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—uterine cancer	3.33e-06	1.6e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—uterine cancer	3.32e-06	1.6e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTEN—uterine cancer	3.3e-06	1.59e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—uterine cancer	3.25e-06	1.56e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EP300—uterine cancer	3.21e-06	1.55e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—uterine cancer	3.21e-06	1.55e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CTNNB1—uterine cancer	3.21e-06	1.54e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKR1C3—uterine cancer	3.2e-06	1.54e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—uterine cancer	3.17e-06	1.53e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—uterine cancer	3.17e-06	1.53e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—uterine cancer	3.16e-06	1.52e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EP300—uterine cancer	3.15e-06	1.51e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—uterine cancer	3.14e-06	1.51e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—uterine cancer	3.13e-06	1.51e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—uterine cancer	3.13e-06	1.51e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—uterine cancer	3.09e-06	1.49e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.08e-06	1.48e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—uterine cancer	3.08e-06	1.48e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—uterine cancer	3.06e-06	1.47e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—uterine cancer	3.05e-06	1.47e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—uterine cancer	3.04e-06	1.46e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—uterine cancer	3.03e-06	1.46e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—uterine cancer	3.01e-06	1.45e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—uterine cancer	3.01e-06	1.45e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NRAS—uterine cancer	3.01e-06	1.45e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—uterine cancer	3e-06	1.45e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—uterine cancer	2.99e-06	1.44e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—EP300—uterine cancer	2.99e-06	1.44e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EP300—uterine cancer	2.98e-06	1.44e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—uterine cancer	2.98e-06	1.43e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—uterine cancer	2.97e-06	1.43e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—uterine cancer	2.96e-06	1.43e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—uterine cancer	2.95e-06	1.42e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRAS—uterine cancer	2.94e-06	1.42e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—uterine cancer	2.94e-06	1.42e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1B—uterine cancer	2.94e-06	1.41e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—uterine cancer	2.93e-06	1.41e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—uterine cancer	2.87e-06	1.38e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—uterine cancer	2.87e-06	1.38e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—uterine cancer	2.86e-06	1.38e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—uterine cancer	2.84e-06	1.37e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—uterine cancer	2.83e-06	1.36e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—uterine cancer	2.83e-06	1.36e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRAS—uterine cancer	2.79e-06	1.34e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—uterine cancer	2.79e-06	1.34e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—uterine cancer	2.79e-06	1.34e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CTNNB1—uterine cancer	2.77e-06	1.34e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—uterine cancer	2.77e-06	1.33e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—uterine cancer	2.77e-06	1.33e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—uterine cancer	2.73e-06	1.31e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—uterine cancer	2.72e-06	1.31e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—uterine cancer	2.7e-06	1.3e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—uterine cancer	2.7e-06	1.3e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—uterine cancer	2.64e-06	1.27e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—uterine cancer	2.61e-06	1.25e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—uterine cancer	2.59e-06	1.25e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—uterine cancer	2.58e-06	1.24e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EP300—uterine cancer	2.58e-06	1.24e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—uterine cancer	2.55e-06	1.23e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—uterine cancer	2.53e-06	1.22e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—uterine cancer	2.53e-06	1.22e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—uterine cancer	2.52e-06	1.21e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.51e-06	1.21e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—uterine cancer	2.5e-06	1.2e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP19A1—uterine cancer	2.5e-06	1.2e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—STK11—uterine cancer	2.5e-06	1.2e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—uterine cancer	2.44e-06	1.18e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—uterine cancer	2.44e-06	1.17e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRAS—uterine cancer	2.41e-06	1.16e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—uterine cancer	2.41e-06	1.16e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—uterine cancer	2.4e-06	1.16e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—uterine cancer	2.38e-06	1.14e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—uterine cancer	2.33e-06	1.12e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—uterine cancer	2.3e-06	1.11e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—uterine cancer	2.3e-06	1.11e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—uterine cancer	2.28e-06	1.1e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—uterine cancer	2.25e-06	1.08e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—uterine cancer	2.23e-06	1.07e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—uterine cancer	2.21e-06	1.06e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—uterine cancer	2.21e-06	1.06e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—uterine cancer	2.2e-06	1.06e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—EP300—uterine cancer	2.19e-06	1.05e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—uterine cancer	2.16e-06	1.04e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—uterine cancer	2.15e-06	1.04e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—uterine cancer	2.13e-06	1.03e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—uterine cancer	2.13e-06	1.02e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—uterine cancer	2.08e-06	9.99e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—uterine cancer	2.04e-06	9.82e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—uterine cancer	1.94e-06	9.36e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—uterine cancer	1.94e-06	9.35e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—uterine cancer	1.91e-06	9.18e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—uterine cancer	1.9e-06	9.15e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—uterine cancer	1.88e-06	9.03e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—EP300—uterine cancer	1.85e-06	8.92e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—uterine cancer	1.85e-06	8.88e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—uterine cancer	1.81e-06	8.69e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—uterine cancer	1.8e-06	8.67e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—uterine cancer	1.77e-06	8.49e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—uterine cancer	1.69e-06	8.15e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—uterine cancer	1.62e-06	7.8e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—EP300—uterine cancer	1.62e-06	7.77e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—uterine cancer	1.6e-06	7.68e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—uterine cancer	1.58e-06	7.62e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—uterine cancer	1.56e-06	7.5e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—EP300—uterine cancer	1.52e-06	7.33e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—EP300—uterine cancer	1.51e-06	7.26e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—uterine cancer	1.37e-06	6.6e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—uterine cancer	1.32e-06	6.37e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—uterine cancer	1.2e-06	5.75e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.13e-06	5.42e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—uterine cancer	1.12e-06	5.39e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.12e-06	5.37e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—uterine cancer	1.04e-06	5.02e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—EP300—uterine cancer	9.95e-07	4.79e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—uterine cancer	9.76e-07	4.7e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—uterine cancer	9.2e-07	4.43e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—uterine cancer	9.12e-07	4.39e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—uterine cancer	7.36e-07	3.54e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—uterine cancer	6.02e-07	2.89e-06	CbGpPWpGaD
